SpecificationsOrganism/cell line/tissueHomo sapiensSexMale or female ([Table 1](#t0005){ref-type="table"})Array typeAgilent Whole Human Genome Microarray 8x60K (v2; one color, Cy3) -- Agilent TechnologiesData formatRaw and processed (normalized expression levels)Experimental factorsRNA samples originate from CD8 T cell populations ([Table 2](#t0010){ref-type="table"}) isolated from cryopreserved peripheral blood mononuclear cells (PBMC). RNA was extracted and amplified by Miltenyi Biotec SuperAmpTM technology.Experimental featuresCD8 T cell populations were purified by flow cytometry from 8 different healthy donors vaccinated with Yellow Fever 17D (donors d1 to d8, [Table 1](#t0005){ref-type="table"}); the populations ("cell types", [Table 2](#t0010){ref-type="table"}) include: A2/NS4b tetramer positive CCR7 + CD45RA + CD8 T cells ("A2_NS4b Naïve-like"), "Total Naïve" (CCR7 + CD45RA +), "Total Tscm" (Stem-cell like memory T: CCR7 + CD45RA + CD58 + CD95 +), "Total CM" (Central Memory: CCR7 + CD45RA-) and "Total Effector" (CCR7-).ConsentSamples were obtained from participants under written informed consent following study protocol approval by the Human Research Ethics Committee of the Canton de Vaud (Switzerland).Sample source locationLausanne, Switzerland

1. Direct link to deposited data {#s0005}
================================

<http://www.dtd.nlm.nih.gov/geo/query/acc.cgi?acc=GSE65804>

2. Experimental design, materials and methods {#s0010}
=============================================

2.1. Experimental design {#s0015}
------------------------

The microarray experiment detailed here was performed in the framework of our recent study on the characterization of CD8 + stem cell-like memory T (CD8 Tscm) cells identified in Yellow Fever YF-17D vaccinees that persist for decades following vaccination [@bb0005]. The design of the microarray analysis was aimed to characterize the genome-wide RNA expression profiles of this population of long-lasting YF-specific CD8 Tscm. The cells of interest were isolated from 8 different vaccinees, spanning up to 17 years of vaccination history, male or female, as detailed in [Table 1](#t0005){ref-type="table"}. YF-specific CD8 Tscm were analyzed and isolated from peripheral blood of the eight vaccinees based on the detection of T cells bearing a TCR specific for the HLA-A\*02-restricted epitope NS4b^214--222^ (LLWNGPMAV) of YF-17D [@bb0005], [@bb0010], within the conventional Naïve gate: for the microarray, they are referred to as "A2/NS4b Naïve-like". As reference populations, various differentiation subsets were also isolated from the total pool of circulating CD8 T cells, including: total Naïve, total CM, and total effectors (CCR7- cells, i.e. a mixture of effector memory (EM) and effector memory CD45RA + (EMRA)). We also isolated the more recently described total population of CD8 Tscm [@bb0015], [@bb0020]. The nomenclature and markers used to isolate these five populations are listed in [Table 2](#t0010){ref-type="table"}.

2.2. Sample collection, preparation & cryopreservation {#s0020}
------------------------------------------------------

Healthy volunteers vaccinated with YF-17D donated circulating leukocytes according to the standards of the Blood Transfusion Center in Epalinges, Switzerland (Service Vaudois de Transfusion Sanguine). Donations were performed either via leukapheresis (all donors except d2) or a standard complete blood donation where the leukocyte-rich fraction (buffy coat) was recovered for the study (d2 only). Peripheral blood mononuclear cells (PBMC) were separated by density gradient fractionation using Lymphoprep™. All samples were immediately cryopreserved in RPMI 1640 supplemented with 40% FCS and 10% DMSO.

2.3. Isolation of CD8 T cell populations {#s0025}
----------------------------------------

Freshly thawed PBMC were first enriched for CD8 T cells using the human CD8 T cell enrichment kit from StemCell™ Technologies (negative selection, per manufacturer\'s instructions). For flow cytometry-based isolation of CD8 T cell populations, stainings were performed using PBS with 5 mM EDTA, 0.2% BSA and 0.2% Na-azide (FACS buffer) and all steps were carried out at 4 °C. Enriched CD8 T cells were first stained with a PE-conjugated HLA-A\*02/NS4b^214--222^ tetramer (TCmetrix Sàrl.) for 40 min, followed by surface staining for 30 min using CD8-Alexa700 (clone HIT8a, Biolegend), CD45RA-ECD (clone 2H4LDH11LDB9, Beckman Coulter), CCR7-BrilliantViolet421 (clone G043H7, Biolegend), CD16-KromeOrange (clone 3G8, Beckman Coulter), CD58-FITC (clone 1C3, BD Biosciences), CD95-PECy7 (clone DX2, Biolegend) and live/dead cell-marker Vivid-Aqua (Molecular Probes®, Invitrogen) for 30 min. The flow cytometry gating and sorting strategy is described in [@bb0005]. From each population of CD8 T cells ([Table 2](#t0010){ref-type="table"}) and each donor ([Table 1](#t0005){ref-type="table"}), 1000 cells were isolated by flow cytometry-based purification using a BD FACSAria I flow cytometer. Purifications were performed on two separate days, with samples from donors d1, d3, d4 and d6 processed in Sort I, and samples from donors d2, d5, d7 and d8 processed in Sort II.

2.4. RNA extraction, amplification (SuperAmp miltenyi biotech) and hybridization onto microarray platform for data collection {#s0030}
-----------------------------------------------------------------------------------------------------------------------------

RNA extraction and amplification were performed using the SuperAmp™ technology from Miltenyi Biotec. Per sample, 1000 cells were purified directly into 13.5 μl of SuperAmp™ lysis buffer (Miltenyi Biotec). RNA lysates were incubated for 10 min at 45 °C and immediately frozen at − 20 °C. Thereafter, frozen RNA lysates were shipped to and processed and analyzed by the Genomic Services of Miltenyi Biotec. The SuperAmp™ technology performs in-column immunomagnetic-based mRNA extraction using paramagnetic oligo(dT) MicroBeads, with bead-bound 1st strand cDNA synthesis and 3′-end tailing for subsequent elution and single-primer global PCR amplification and Klenow labeling. The cDNA samples were controlled for integrity by analysis on Agilent 2100 Bioanalyzer. Samples were hybridized onto Agilent Whole Human Genome Microarray 8x60K (V2, one color: Cy3) and fluorescence signals were detected using Agilent\'s Microarray Scanner System (Agilent Technologies). The image files were processed with the Agilent Feature Extraction Software to yield probe intensities. The 40 samples (8 donors × 5 cell populations) were randomly distributed on a total of 5 microarray slides with 8 spots per slide. In the files uploaded into the GEO repository (GSE65804), the name of the raw data file contains the 12-digit code of the microarray slide (e.g. 253949422880) as well as the spot position of the sample within that slide (1.1--1.4 and 2.1--2.4). Supplementary Material 2 provides a sample annotation table, relating the raw data file names to the name and characteristics of the donor (d1 to d8, [Table 1](#t0005){ref-type="table"}) and the "cell type" ([Table 2](#t0010){ref-type="table"}).

3. Microarray data: quality controls and exploratory analysis {#s0035}
=============================================================

3.1. Data pre-processing {#s0040}
------------------------

The raw data from the Agilent Feature Extraction software was processed and analyzed in R, using mainly functions from the limma package. The code that was used to generate the figures in this manuscript, starting from the raw data deposited in GEO, is available in Supplementary Material 1. Supplementary Materials 2 and 3 contain the sample annotation tables that are used in the computational analyses, with 'sample info' and 'targets' specified, respectively.

The raw data ([Fig. 1](#f0005){ref-type="fig"} A) was background-corrected using the "normexp" algorithm implemented in limma, and thereafter normalized between the arrays using quantile normalization. All samples were considered to be of good quality. In addition to the expression values, the Agilent Feature Extraction software provides (among other things) flags indicating whether or not a given feature is detected above the background level. We used this information to filter out all probes that were not detected well above the background (defined as the estimated background level + 2.6 times the estimated standard deviation of the background) for any of the samples. This reduced the number of features from the original 62,976 to 50,477. Finally, we averaged the expression of replicated probes and filtered out control probes. This further reduced the number of analyzed features to 41,923. Mapping from probe names to gene identifiers was done using the information provided by the Agilent Feature Extraction software. [Fig. 1](#f0005){ref-type="fig"} B displays the distribution of intensity values after the pre-processing.

3.2. Exploratory analysis {#s0045}
-------------------------

We used Principal Component Analysis (PCA) to perform exploratory analysis in order to summarize and visualize the data, as well as to detect potential artifacts and effects of experimental and technical parameters. The panels of [Fig. 2](#f0010){ref-type="fig"} show the same two-dimensional PCA sample representation (PC1 *versus* PC2) based on all 41,923 probes, colored according to various sample attributes. No association with any of the recorded technical parameters can be seen, including: "the day of cell sorting" (sort I *vs.* sort II), the position of the samples depending on the "microarray slide" or "microarray spot", the "donor" or the "gender" of the donor. The second principal component shows some discrimination between the cell populations ("cell type", top-left panel of [Fig. 2](#f0010){ref-type="fig"}).

Since we expected the differences between the different T-cell populations to affect a relatively small set of genes, we further performed exploratory analysis after restricting the data set to the 10% probes with the highest variance across the 40 samples. Again, no clear impact of any of the recorded technical parameters was seen (Supplementary Material 1), but the first principal component clearly ordered the five cell populations along a gradient of differentiation ([Fig. 3](#f0015){ref-type="fig"}) --- this observation is discussed in our recently published study [@bb0005]. After reducing the variable set further to keep only the top 1% probes with highest variance across the samples, the cell population gradient still dominated the first principal component. Considering all the other technical and experimental parameters enumerated above, the analysis showed that the second principal component distributed samples according to gender ([Fig. 4](#f0020){ref-type="fig"}). The highest weights in the second principal component were assigned to probes corresponding to genes located on the sex chromosomes ([Table 3](#t0015){ref-type="table"}), several of which have been previously shown to be strongly associated with gender [@bb0025], [@bb0030], [@bb0035].

Appendix A. Supplementary data {#s0050}
==============================

Supplementary material 1Supplementary material 2Supplementary material 3
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![Signal intensity distribution (raw and processed data). A. Signal intensity distribution of raw data from all microarray probes, vertically aligned per sample. B. Signal intensity distribution after the processing steps described in the text (background subtraction, quantile normalization, filtering, summarization and exclusion of control probes), vertically aligned per sample. The samples are colored by the "cell type" annotation.](gr1){#f0005}

![Principal component analysis based on all genes: no detectable influence of observed technical or experimental parameters. Two-dimensional representations of PC1 versus PC2 for all samples colored as indicated according to "Day of cell sorting", "microarray slide", "microarray spot", "donor" (ordered by increasing years since vaccination), "gender" of the donor and "cell type".](gr2){#f0010}

![PCA based on the 10% most variable probes: differentiation gradient in PC1 according to cell type. Two-dimensional representation of PC1 versus PC2 for all samples colored according to "cell type". Additional colorings, showing no association between the first two principal components and the other observed technical and experimental parameters, are available in Supplementary Material 1.](gr3){#f0015}

![PCA based on the 1% most variable probes: differentiation gradient in PC1 according to cell type and gender differences in PC2. Two-dimensional representations of PC1 versus PC2 for all samples colored according to "cell type" (showing a differentiation gradient in PC1) and to "gender" (showing gender differences in PC2). Additional colorings, showing no association between the first two principal components and the other observed technical and experimental parameters, are available in Supplementary Material 1.](gr4){#f0020}

###### 

Donors (YF-17D vaccinees) from whom the 5 different T cell populations were isolated.

  Donor   Gender   Age    Years since YF-17D vaccination   Isolation (sort) day
  ------- -------- ------ -------------------------------- ----------------------
  d1      Female   25.4   2.4                              I
  d2      Female   25.9   4.1                              II
  d3      Female   26.8   7.2                              I
  d4      Male     33.6   7.9                              I
  d5      Female   30.7   8.7                              II
  d6      Female   23.6   12.1                             I
  d7      Male     41.4   12.7                             II
  d8      Male     26.6   17.8                             II

###### 

T cell populations ("cell types") isolated from each donor for microarray analysis. All populations were sorted from CD8 T-enriched samples by gating within live (Vivid aqua-) CD8 + CD16- cells after doublet exclusion.

  -------------------------------------------------------------------------------------------------------------------------
  Sample title in GEO database   T cell population                                Markers used for flow cytometry sorting
  ------------------------------ ------------------------------------------------ -----------------------------------------
  A2_NS4b\_ naivelike            YF-17D-specific CD8 T cells, naïve-like (Tscm)   A2/NS4b +\
                                                                                   CCR7 + CD45RA +

  total_naive                    Naïve in total CD8 T                             CCR7 + CD45RA +

  total_Tscm                     Tscm in total CD8 T                              CCR7 + CD45RA +\
                                                                                   CD95 + CD58 +

  total_cm                       CM in total CD8 T                                CCR7 + CD45RA-

  total_effector                 Effectors (EM + EMRA) in total CD8 T             CCR7-
  -------------------------------------------------------------------------------------------------------------------------

###### 

Probes (and corresponding genes) with largest weight on the second principal component in PCA based on the 1% probes with highest variance. This component discriminates between male and female donors, and is dominated by probes measuring the expression of genes located on the sex chromosomes. Probes with positive weight are highly expressed in the female donors, and probes with negative weight are highly expressed in the male donors.

  PC2, positive weight                 PC2, negative weight
  ------------------------------------ ------------------------------------
  A_33_P3405911 (TSIX, chrX)           A_23_P364792 (TXLNG2P, chrY)
  A_19_P00316565 (TSIX, chrX)          A_21_P0006594 (TTTY15, chrY)
  A_19_P00327297 (XLOC_008015, chrX)   A_23_P324384 (RPS4Y2, chrY)
  A_19_P00320438 (TSIX, chrX)          A_21_P0006606 (XLOC_008323, chrY)
  A_19_P00326132 (TSIX, chrX)          A_23_P259314 (RPS4Y1, chrY)
  A_19_P00321129 (TSIX, chrX)          A_33_P3725324 (USP9Y, chrY)
  A_19_P00331623 (XIST, chrX)          A_23_P137238 (KDM5D, chrY)
  A_19_P00321917 (TSIX, chrX)          A_23_P160004 (UTY, chrY)
  A_19_P00806762 (TSIX, chrX)          A_33_P3261353 (BCORP1, chrY)
  A_21_P0006456 (XLOC_008185, chrX)    A_21_P0006651 (XLOC_008386, chr10)
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